The Price Reset: How Governments Everywhere Rewrote the Rules of Drug Pricing.

The Price Reset: How Governments Everywhere Rewrote the Rules of Drug Pricing.

July 2026

The way the world pays for medicines is being rewritten, and it is happening across major pharmaceutical markets. For most of the past decade, the story was easy to tell and easy to get wrong: headlines tracked list prices, list prices rose, and everyone concluded that medicines were simply becoming more expensive. What is happening now is different in kind. Across the United States, Europe, the United Kingdom, China, and the emerging markets, governments are intervening in how drugs are priced at the same time and with unusual force — the most concentrated wave of pharmaceutical pricing reform in a generation.

For the leaders we advise, this is not a compliance update. It is a structural change in the commercial logic of the industry, and it lands squarely in the domain of public affairs and communications. Three assumptions that held five years ago no longer do: that governments will leave pricing largely to the market, that the United States will keep quietly subsidizing lower prices everywhere else, and that where a company manufactures has nothing to do with what it can charge. Each has now been overturned by policy — deliberately, and mostly in the past twelve months.

This Confident View Ahead sets out the global picture in plain language and explains what it means for the executives who must now defend prices, protect reputation, and shape policy. It is a condensed reading of a much larger body of work. In the coming weeks, we will publish a companion piece on scenario planning for this reset — the specific futures leaders should prepare for and the moves that pay off under each. For the full landscape and those scenarios now, contact CSG directly.

1. The fact the whole debate turns on: list prices up, net prices down

Start with the single most important and least understood fact in this subject. In the United States in 2025, the average list price of a brand-name drug rose about 3.5 percent — the slowest growth in at least a decade — while the average net price, the amount actually collected after rebates and discounts, fell.[1] Once inflation is accounted for, real net prices have now declined for the eighth consecutive year. Rebates and discounts cut the typical brand list price roughly in half, and the gap between the two — what analysts call the gross-to-net bubble — reached 356 billion dollars in 2024.[2]

The sticker price and the receipt have been drifting apart for years. Nearly every headline quotes the sticker; nearly every policy targets the receipt.

This matters for anyone responsible for reputation. Almost every alarming headline about drug prices cites the list price, while almost every government policy targets the net price. The two are drifting apart, and the space between them is where most of the public argument now lives. Globally, the direction is still growth — IQVIA projects the world medicine market expanding 5 to 8 percent a year to around 2.6 trillion dollars by 2030 — but it is slower, more heavily rebated growth, driven above all by obesity and diabetes drugs.[3]

Washington can credibly demand lower prices because the United States genuinely does pay far more than its peers. RAND’s most-cited comparison found US prices averaging 2.78 times those of 33 other wealthy nations, and 4.22 times as much for brand-name drugs specifically.[4] Tellingly, American generics — about 9 in 10 prescriptions — are actually cheaper than the international average. That single asymmetry, expensive brands and cheap generics, explains most of the policy that follows.

2. The United States: six levers, one direction

The defining feature of US policy in this period is not any single measure but the fact that six of them are arriving together. Analysts call it policy stacking, and it is the right frame: Medicare price negotiation, Most-Favored-Nation pricing, a new family of Medicare and Medicaid demonstration models, pharmacy-benefit-manager reform, a government retail channel, and pharmaceutical tariffs are all landing inside roughly eighteen months, each interacting with the others.[5] No manufacturer can now plan around one of these levers in isolation.

Medicare negotiation is now settled law. The first ten negotiated prices took effect on 1 January 2026, with cuts of 38 to 79 percent off the list price. A second round of fifteen drugs — including the semaglutide family, Ozempic and Wegovy — was settled for 2027 at an average 44 percent reduction, and a third round of fifteen more, the first to include physician-administered drugs, was selected for 2028.[6] The industry fought this in court for two years and lost repeatedly; in May 2026, the Supreme Court declined to hear the consolidated challenges, leaving the program intact.[7] The venue for changing it is now Congress and the ballot box, not the bench.

International reference pricing is being exported from Washington. A May 2025 executive order directed that Americans should pay no more than the lowest price charged in a comparable wealthy country. Rather than impose this by regulation, the administration pursued voluntary bilateral deals; by April 2026, seventeen manufacturers had signed, covering what the White House says is about 86 percent of the branded market.[8] Its consumer-facing site is TrumpRx.gov, a government-run platform launched in February 2026, offering cash discounts averaging around 50 percent. Behind the deals sit rules that do not depend on any company’s goodwill — a family of Medicare and Medicaid models (GENEROUS, GLOBE, GUARD and BALANCE) that hardwire foreign benchmarks into public programs, including a Medicare GLP-1 Bridge offering eligible beneficiaries obesity drugs for $50 a month starting July 2026.[9]

Read the fine print

The White House projects that the Most-Favored-Nation framework will save between $529 billion and nearly $600 billion over 10 years; modeled by administration economists and not independently validated: deal terms are largely undisclosed, the retail platform mainly helps cash-paying uninsured patients rather than the insured majority, and every one of the deal-signers still raised some list prices in January 2026. The direction is real; the magnitude is a claim, not yet a result.

The rebate machine is being unwound. Federal PBM reform, signed in February 2026, delinks middleman pay from the price of the drug, requires that rebates pass through to plans, and mandates transparency — an attack on the gross-to-net bubble at its source. And yet the traditional January ritual continued: manufacturers raised list prices on more than 870 brands in the first two weeks of 2026, at a median increase of about 4 percent, even as out-of-pocket caps for patients deepened.[10] Six levers, one direction. This is no longer a set of policies; it is an operating system for US drug pricing.

3. Tariffs have become pricing policy

Trade policy belongs in a pricing discussion because the administration has deliberately fused the two. Using Section 232 of the Trade Expansion Act, which permits tariffs on national-security grounds, it has proclaimed a 100 percent tariff on patented pharmaceutical imports. Timing is where the public conversation keeps going wrong. A 100 percent tariff announced on social media in September 2025 was never implemented; the operative instrument is a formal proclamation of April 2026 that sets the machinery in motion with a delay, with the first tranche scheduled for 31 July 2026 and broader application at the end of September.[11] As of today, not a single 100 percent pharmaceutical tariff is being collected. Every ‘tariffs hit pharma’ headline should be read against that calendar.

The tariff is a menu of ways to avoid the headline rate

Onshoring plus a price deal, 0 percent. Onshoring alone, 20 percent, rising toward 100 percent over four years. The United Kingdom, 10 percent with a path to zero. The EU, Japan, Korea, and Switzerland are 15 percent under their trade frameworks. Generics and biosimilars are exempt — for now- and under review around April 2027. Default for patented drugs with no deal: 100 percent.

The escape hatches are the point. Because a company can move from 100 percent to zero by pledging US manufacturing and lower prices, the tariff functions less as a revenue measure than as leverage — and it has worked. Independent trackers put US investment commitments at nearly $370 billion across roughly 20 new sites, led by pledges from Johnson & Johnson, Roche, AstraZeneca, Eli Lilly and Novartis.[12] The exposed flank is generics: the makers who supply 9 in 10 US prescriptions on wafer-thin margins depend on active ingredients that come roughly 80 percent from China and India, and tariffs on those inputs could deepen the drug shortages the US already struggles with.[13] Their exemption is the single largest uncertainty in the whole picture.

4. GLP-1s: the class that made pricing political

If one product category explains why drug pricing became a first-order political issue, it is the GLP-1 medicines for diabetes and obesity. They are the clearest illustration of the US price gap, the biggest single prize in the Medicare negotiations, and the test case for almost every new mechanism at once. List prices around 1,000 to 1,350 dollars a month have been pushed through direct-to-consumer channels to roughly 350, and as low as 199 for some doses; Medicare’s negotiated semaglutide price, effective 2027, is about 274 dollars a month.[6]

Why the international gap is politically radioactive

Monthly semaglutide runs roughly 83 dollars in France, 93 in the UK, and 147 in Canada, compared with close to 900 on the US list. A gap of that size, on a drug tens of millions of people want, is what makes Most-Favored-Nation pricing politically difficult to amend even where economists question its design.

A second turning point arrived in April 2026, when the US approved the first oral GLP-1 for weight loss — the fastest new-medicine approval since 2002, priced from around 149 dollars a month self-pay.[14] A pill breaks the injection, cold-chain and supply constraints that defined the first wave, and moves the competitive battleground decisively toward price and access. The clinical story is not yet closed — regulators have asked for extensive long-term safety data — but the commercial signal is unmistakable.

5. The rest of the world is moving in the same direction

Europe is reforming and worrying at the same time. The EU struck its pharma package deal in December 2025, landing on more generous data protection for innovators — a shift widely read as a response to competitiveness fears.[15] Those fears are quantified: Europe’s share of global pharmaceutical R&D has shrunk by about a quarter over 20 years, and between 2019 and 2023, only about 16 percent of new medicines were launched first in Europe, compared with 67 percent in the United States.[16] The uncomfortable subtext is that Most-Favored-Nation pricing gives manufacturers a reason to launch later, or higher, in Europe, because every low European price now feeds the American benchmark.

The United Kingdom is the year’s sharpest cautionary tale. Its voluntary rebate rate on newer medicines spiked to a record 22.9 percent in 2025 — multiples of the 5 to 9 percent paid in comparable European countries — and the consequences were immediate: a collapsed renegotiation, a canceled billion-pound London research center, and close to two billion pounds of planned investment paused or pulled.[17] The resolution came bundled into trade policy. A December 2025 UK-US deal secured zero US tariffs on British pharma exports for three years in exchange for higher NHS spending on new medicines and a capped rebate rate — a template for how Washington now trades tariff relief for pricing and access concessions abroad.[18]

China has become the place where the next generation of drugs is invented. At home, the state keeps driving prices down hard, cutting newly listed drugs by around 60 percent and procurement prices by 70 percent or more. But cross-border out-licensing from Greater China reached a record of roughly 138 billion dollars in 2025, nearly ten times the 2021 figure, and China now accounts for an increasing share of global drug development.[19] Chinese-originated molecules carry markedly lower upfront costs, giving Western firms a cheaper way to refill pipelines as the patent cliff bites.

And the emerging markets face an access reckoning. The core patents on semaglutide began expiring in 2025 and 2026; generic versions launched in India in March 2026 for as little as $15 a month, and academics estimate they could eventually be produced for a few dollars and reach 160 countries.[20] Where a drug that tens of millions of people need is patented at Western prices but manufacturable for a few dollars, governments reach for compulsory licensing — Brazil is already debating bills to do exactly that. Expect access, not just cost, to become the dominant pricing argument in the global South over the next two years.

6. What this means for leaders

Strip away the acronyms, and a few durable conclusions remain — the ones we would put in front of a board.

  • The era of the quiet US subsidy is ending. For decades, high American prices effectively paid for lower prices everywhere else. The new tools are designed to stop that, and the underlying public anger is bipartisan enough that they will not simply reverse with a change of administration. Any strategy that assumes the US will pay a premium indefinitely is planning for a world that is closing.
  • Where you make it is now part of what you can charge. The tariff regime has fused manufacturing location with market access. The 370 billion dollars in onshoring pledges is the market voting with its capital.
  • The gap between the list and the net is becoming indefensible in public. PBM reform, a public retail channel, and transparency rules are all converging on the same target. Organizations that can tell a clear, honest story about what a medicine actually costs — and who keeps the difference — will hold a real reputational advantage over those still defending the old opacity.
  • Launch sequencing is now a global chess problem. Because a price in one country feeds reference calculations in others, the old playbook of launching cheaply in smaller markets first is actively dangerous. Every price is now a public precedent.
  • This is a public-affairs challenge as much as a commercial one. The companies that navigate the reset well will be those that engage governments early, argue in plain language and get ahead of the access debate — not the ones that treat every measure as something to fight and every price as something to hide.

The next competitive advantage in this industry is credibility. When governments, patients, and payers all suspect the numbers, the organization that can be trusted about its own prices, supply chain, and value will win the arguments the others lose.

Coming next — and how to go deeper

This article is a condensed reading of CSG’s full strategic intelligence work on the price reset. In the coming weeks, we will publish a companion scenario-planning article mapping the specific futures leaders should prepare for and the moves that pay off under each. For a fuller discussion of the current landscape and those scenarios now — including the market-by-market detail behind this overview — contact Confident Strategy Group directly.

Why Confident Strategy Group

Confident Strategy Group works at the intersection of business transformation and societal expectation. We help leaders in healthcare and life sciences read where policy, regulation and public sentiment are heading, shape credible positions before scrutiny arrives, and turn complex pricing and access questions into clear, defensible narratives for governments, payers, investors and the public. Our CEO has over 20 years of in-house experience at Wyeth, Pfizer, and Bayer, including developing innovative pricing programs. In a reset this fast-moving, our value is helping organizations move decisively without losing trust.

This overview was developed using Confident ForeFront, CSG’s radar tool for tracking emerging policy, regulatory and reputational signals across markets.

Conclusion

The reset is happening. Governments across every major market are pushing net prices down deliberately rather than accidentally, and they are using price negotiation, international benchmarking, and trade policy together to do it. The industry’s traditional pricing model has quietly stopped working — not in one country, but across the whole system. The winners of the next five years will be the organizations that accept this early and adapt across their entire footprint, rather than litigating market by market toward the same conclusion. The only real choice left is whether to shape the reset or be shaped by it.

References

Selected sources: all live as of 8 July 2026. Figures are drawn from government bodies and recognized industry analysts (CMS, KFF, RAND, IQVIA, EFPIA, ABPI, the White House) and reputable trade and news outlets. Where a policy is proposed, scheduled or contested rather than in effect, that is flagged in the text.

  1. Drug Channels (Adam J. Fein / SSR Health), S. Brand-Name Drug Prices Fell in 2025, Jan 2026.
  2. Drug Channels, Gross-to-Net Bubble Hits $356B in 2024, Jul 2025.
  3. IQVIA Institute, Global Medicine Use Trends 2026, Mar 2026.
  4. RAND, International Prescription Drug Price Comparisons (2022 data), Feb 2024.
  5. Simon-Kucher, Policy stacking and system logic: 2026 ushers a new era of US drug pricing.
  6. CMS, negotiated prices for 2026-2028 (Rounds 1-3), fact sheets, 2026; NPR/CMS on Round 2 semaglutide pricing, Nov 2025.
  7. Fierce Pharma / IPWatchdog, Supreme Court declines to hear IRA negotiation challenges, May 2026.
  8. The White House, MFN executive order (May 2025) and 17-manufacturer fact sheet (Apr 2026); STAT News / CNBC on TrumpRx.gov.
  9. Hogan Lovells; Covington & Burling; CMS, CMMI models GENEROUS, GLOBE, GUARD, BALANCE and the Medicare GLP-1 Bridge, Dec 2025 – Jul 2026.
  10. NPR / 46brooklyn / 3 Axis Advisors, 872 brand price rises within two weeks, Jan 2026; CMS, Part D out-of-pocket cap and PBM reform (Consolidated Appropriations Act, Feb 2026).
  11. The White House, Adjusting Imports of Pharmaceuticals (Section 232 proclamation), 2 Apr 2026; CNBC/Bloomberg on the Sep 2025 announcement (not implemented).
  12. Fierce Pharma / DPR Construction, US pharma manufacturing tracker (~$370bn across ~20 sites), 2026.
  13. Association for Accessible Medicines; Brookings, on tariffs, shortages and API dependence (~80% from China and India).
  14. STAT News / Eli Lilly; NBC News, first oral GLP-1 for weight loss approved and post-market safety data requested, Apr 2026.
  15. Council of the EU, Pharma package: Council and Parliament reach a deal, 11 Dec 2025.
  16. EFPIA, The Pharmaceutical Industry in Figures 2025.
  17. ABPI, VPAG payment rate (2025: 22.9%; 2026: 14.5%), Dec 2025; STAT / European Pharmaceutical Review on UK investment pullbacks.
  18. UK / USTR; Morgan Lewis, UK-US pharmaceutical trade deal, Dec 2025.
  19. Pharmasource / BioPharma Dive, China out-licensing record (~$138bn, 2025); Greenberg Traurig, China ~20% of global drug development.
  20. Pearce IP / CNBC; medRxiv / STAT, generic semaglutide launches in India and production-cost analysis, Mar 2026; Licks Attorneys, compulsory-licensing bills in Brazil, 2026.

Confident Strategy Group —  www.confidentstrategygroup.com. This Confident View Ahead is provided for information and does not constitute legal or financial advice. Prices, dates and policy statuses are as of 8 July 2026; several remain proposed, scheduled or contested and are flagged in the text. Analysis powered by Confident ForeFront.

Our Work >